Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Defymed
Strasbourg, Grand Est, Francedefymed.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
Defymed’s lead program, ExOlin®, an implantable device for physiological insulin administration, has received approval to start a pilot clinical study. The company’s other main product, MAILPAN®, a bioartificial pancreas, remains in advanced preclinical development. Both aim to improve outcomes and quality of life for type 1 diabetic patients who do not respond well to conventional therapies.
- Therapeutic areas
- Endocrinology
- Modalities
- Bioartificial organsImplantable medical devices
- Industry
- Therapeutic Medical Devices
02
Partnerships
IRCADJDRF
Beyond the preview
Go deeper on Defymed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Defymed.